Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature

Ustekinumab, a monoclonal antibody against interleukin (IL)-12 and IL-23 approved for the treatment of Crohn’s disease, has shown to be an effective therapy with a favourable safety profile. Clinical trials and real-world studies have reported very few neurological adverse events, including posterio...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarto, Jordi, Caballol, Berta, Berenguer, Joan, Aldecoa, Iban, Carbayo, Álvaro, Santana, Daniel, Archilla, Ivan, Gaig, Carles, Graus, Francesc, Panés, Julián, Saiz, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883387/
https://www.ncbi.nlm.nih.gov/pubmed/35237349
http://dx.doi.org/10.1177/17562864221079682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883387/
https://www.ncbi.nlm.nih.gov/pubmed/35237349
http://dx.doi.org/10.1177/17562864221079682

Ejemplares similares